A Study to Evaluate the Efficacy and Safety of Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Dupilumab (Primary)
- Indications Peanut hypersensitivity
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 02 Jan 2019 Status changed from planning to not yet recruiting.
- 10 Aug 2018 New trial record
- 02 Aug 2018 According to a Regeneron Pharmaceuticals media release, this study is expected to initiate later in 2018.